[CytoReason in PR Newswire] CytoReason extends its collaboration with Sanofi to advance AI-driven drug discovery
TEL AVIV, Israel, Jan. 9, 2026 /PRNewswire/ — CytoReason, a leader in AI-powered computational disease modeling, today announced the expansion of its collaboration with Sanofi for the third time. This multi-year agreement, valued at up to $16 million, further solidifies their partnership. Read...
Read More